Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems

Authors:	Boussery Koen De Smet Julie De Cock Pieter Vande Velde Saskia Mehuys Els De Paepe Peter Remon Jean Paul Van Bocxlaer Jan F P Van Winckel Myriam

Affiliation:	Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Gent, Belgium. koen.boussery@ugent.be

Abstract:	AIMS Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems. METHODS Nonblinded, two-phase cross-over trial. RESULTS In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS® formulation. Median (90% confidence interval) area under the plasma concentration–time curve ratio (MUPS® over suspension) was 0.5 (0.06–2.37). CONCLUSIONS In this population, omeprazole MUPS® formulation has no apparent advantage over the more easily administered suspension formulation.

Keywords:	bioavailability cerebral palsy feeding tube neurodevelopmental problem omeprazole proton pump inhibitor
本文献已被 PubMed 等数据库收录！